A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase

DNA damage activates Checkpoint kinase 1 (Chk1) to halt cell cycle progression thereby preventing further DNA replication and mitosis until the damage has been repaired. Consequently, Chk1 inhibitors have emerged as promising anticancer therapeutics in combination with DNA damaging drugs, but their...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurikar, Nandini, Thompson, Ruth, Montano, Ryan, Eastman, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811467/
https://www.ncbi.nlm.nih.gov/pubmed/26595527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811467/
https://www.ncbi.nlm.nih.gov/pubmed/26595527

Ejemplares similares